LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "arac" as a keyword



Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine.

Sign Up to like & get
recommendations! Published in 2025 at "Molecular oncology"

DOI: 10.1002/1878-0261.70124

Abstract: Relapsed/refractory (R/R) disease is a major hurdle to long-term survival of acute myeloid leukemia (AML) patients treated with intensive cytarabine (AraC)-based chemotherapy. R/R AML salvage treatment with venetoclax (VEN) + azacitidine (AZA) results in overall response rates… read more here.

Keywords: cdk9; aml cell; arac; cell death ... See more keywords

Changes in cognition and dendritic complexity following intrathecal methotrexate and cytarabine treatment in a juvenile murine model

Sign Up to like & get
recommendations! Published in 2018 at "Behavioural Brain Research"

DOI: 10.1016/j.bbr.2017.12.008

Abstract: HighlightsMTX/AraC significantly compromised the dendritic architecture.MTX/AraC modulated spine morphology throughout Hippocampus.MTX/AraC impaired hippocampal dependent behavior. ABSTRACT Acute lymphoblastic leukemia (ALL) is the most prevalent childhood cancer and accounts for 26.8% of cancer diagnoses among children,… read more here.

Keywords: treatment; juvenile; cognition dendritic; arac ... See more keywords

Loss of Cystathionine-β-Synthase Activity Results in Increased Oxidative Phosphorylation and Cytarabine Resistance in Myeloid Leukemia Associated with Down Syndrome

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-203961

Abstract: Acute myeloid leukemia (AML) and myelodysplasia in children with Down syndrome (DS) collectively define myeloid leukemia associated with DS (ML-DS) according to the WHO 2016 classification. DS individuals are genetically predisposed to hematologic malignancies, including… read more here.

Keywords: resistance; arac; arac resistant; cell ... See more keywords

Association of Glasdegib + Low-Dose Cytarabine (AraC)) in the Real-Life Treatment of Very Frail Elderly Acute Myeloid Leukemias (AML) Patients

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-206787

Abstract: Background Survival of very frail/elderly patients (pts) with Acute Myeloid Leukemia (AML) not eligible for standard induction chemotherpy is very poor. Recently, the association of glasdegib + low-dose cytarabine (AraC) was registered for these pts,… read more here.

Keywords: arac; response; aml; frail elderly ... See more keywords

Old Meets New: Hydroxyurea Synergistically Enhances the Antileukemic Activity of Gilteritinibagainst FLT3-ITD AML

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-207855

Abstract: About 25% of acute myeloid leukemia (AML) cases harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations which is associated with poor prognosis. Gilteritinib is a second generation FLT3 inhibitor approved for treating… read more here.

Keywords: flt3 itd; gilteritinib; flt3; arac ... See more keywords